Reuters logo
BRIEF-Reata Pharma receives orphan drug designation for Omaveloxolone
2017年9月13日 / 晚上9点38分 / 2 个月前

BRIEF-Reata Pharma receives orphan drug designation for Omaveloxolone

Sept 13 (Reuters) - Reata Pharmaceuticals Inc

* Reata Pharmaceuticals Inc receives orphan drug designation for Omaveloxolone for the treatment of malignant melanoma

* Reata Pharmaceuticals Inc - ‍FDA granted orphan designation to Omaveloxolone for treatment of stage IIb through IV malignant melanoma​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below